At a glance
- Originator Metabasis Therapeutics
- Class Small molecules
- Mechanism of Action Adenosine deaminase inhibitors; AMP deaminase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Ischaemic heart disorders
Most Recent Events
- 29 Oct 1998 New profile
- 29 Oct 1998 Preclinical development for Ischaemic heart disorders in USA (Unknown route)